Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Forum Arrowhead Research geopend
Volgen
Een droom om ons op te beuren (met dank aan BioBoyScout): No doubt we need proof of concept that RNAi works in the lung. Theoretically, MMP7 could be very effective in treating IPF. My guess is that a yearly price of $75k is extremely conservative, but that depends on how effective the drug is. Arrowhead probably won't go forward with the drug if it doesn't command at least a $75k price tag. So if you run the numbers for this drug, it would easily end up conservatively dosing 50k people worldwide within a few years. That's a minimum of $3.75 billion a year! This one drug alone could conservatively make this a $6B market cap company in phase 1 (15% probably of success), $12B MC in phase 2 (30% POS), and $25B MC in phase 3 (just a 60% POS). Here are two very compelling articles about how effective MMP7 (matrilysin) may be to control IPFwww.pnas.org/doi/10.1073/pnas.092134099 www.sciencedirect.com/topics/biochemi... The more you dig in, the more there is to like. It should also be noted that if this drug works, approval should be very quick, and accelerated approval would be a near certainty. Also, since it's an orphan drug, Arrowhead will either keep it wholly-owned, or partner in a similar way as was done with Takeda. The more I dig into this drug and this disease, the more significant it becomes. Trying to find patients, like for AAT, is not an issue, as basically all 100k patients in the US have been diagnosed and are known. That's HUGE, because doctors would want to start any known effective treatments asap, as IPF is basically a 3 year death sentence. So not only will it be significantly easier to find and enroll patients for trials (and eventually sales), but sales/marketing/commercialization should be significantly easier. On top of it, there are approximately 30k new patients each year in the US alone. So applying what I believe to be conservative numbers, a 5% probability of success (POS) currently values this drug at approximately $1 billion (that's right, a "B" for BILLION). A 15% POS at just under $4B (would most likely be used in phase 1 if proof-of-concept for lung is shown). A 30% POS = over $9B (would be used at phase 2 if over a 50% knockdown of MMP7 is shown). A 60% POS = approximately $22B (would be used at phase 3). A 100% POS = over $40B (would be used if Accelerated Approval is granted). These numbers are for ARO-MMP7 ALONE, and do not include other drugs. One more thought, IF proof-of-concept is shown AND MMP7 knockdown is over 50% (theoretically it would at least double the 3 years of life to 6 years), these valuation numbers would need to be revisited and will most likely go up by at least 2 times from what I just posted. I am assuming just $75k per year for this drug, and if it actually works well, the price could easily be 2-3x that.
Hulskof schreef op 5 december 2022 15:35 :
[...]
Is pure zekerheid, volgens mij. Je weet nooit waar je voor komt te staan, dus het hebben van een plan B is altijd verstandig.
Kan ook fungeren als klein poison pilletje indien nodig
Eerste patiënt ingeschreven voor fase 1-onderzoek naar jicht. Milestone van 15 miljoen. PASADENA, Calif.--(BUSINESS WIRE)--Dec. 8, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million milestone payment, in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457, previously known as ARO-XDH. HZN-457 is a small interfering RNA (siRNA) candidate designed to treat gout by silencing liver xanthine dehydrogenase. The development of HZN-457 is part of a global collaboration and license agreement that the Company entered in 2021 with Horizon. ir.arrowheadpharma.com/news-releases/...
het geld blijft mooi binnen komen , mr dit is niet het nieuws waar we zitten op te wachten
Hulskof schreef op 8 december 2022 14:08 :
Eerste patiënt ingeschreven voor fase 1-onderzoek naar jicht.
Milestone van 15 miljoen.
PASADENA, Calif.--(BUSINESS WIRE)--Dec. 8, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million milestone payment, in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457, previously known as ARO-XDH. HZN-457 is a small interfering RNA (siRNA) candidate designed to treat gout by silencing liver xanthine dehydrogenase. The development of HZN-457 is part of a global collaboration and license agreement that the Company entered in 2021 with Horizon.
ir.arrowheadpharma.com/news-releases/... Die Sirna moet al panklaar op de plank hebben gelegen inclusief veiligheidsonderzoek. Gevonden geld dus.
Volgens Dirk is er vrijdag jongstleden $ 250 miljoen opgehaald. Allemaal in het kader van ARO-AAT??twitter.com/RNAiAnalyst/status/160098... Het verklaart de dip vandaag in ieder geval.
Tom3 schreef op 8 december 2022 23:58 :
$32 per stuk, het staat er echt:
ir.arrowheadpharma.com/node/17626/html Is volgens mij gewoon een voortzetting van de shelf die afliep. Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time t hrough Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $250,000,000 on the terms set forth in this agreement (this “Agreement”).
Ja ik geloof dat Dirk er nu (ook) achter gekomen is dat de vorige overeenkomst gesloten is. Dus storm in glas water :-) Heeft wel een dip in de koers veroorzaakt trouwens.
Tom3 schreef op 9 december 2022 13:52 :
Ja ik geloof dat Dirk er nu (ook) achter gekomen is dat de vorige overeenkomst gesloten is. Dus storm in glas water :-) Heeft wel een dip in de koers veroorzaakt trouwens.
Ik heb daar gisteren nog even gebruik van gemaakt door nog wat stukjes binnen te harken. De AAT data en trial design zullen nu toch wel snel komen...
Hulskof schreef op 9 december 2022 15:07 :
[...]
Ik heb daar gisteren nog even gebruik van gemaakt door nog wat stukjes binnen te harken.
De AAT data en trial design zullen nu toch wel snel komen...
Weer te vroeg m'n kruit verschoten, zie ik. ;-)
Hier hetzelde verhaal , aan 32,57$ ;(
Seizethemoney schreef op 9 december 2022 15:57 :
Hier hetzelde verhaal , aan 32,57$ ;(
Ik gooi ze gewoon op de grote hoop en wacht geduldig af.
Zojuist in een brief van de hersenstichting gelezen dat de FUS technologie kansrijk is. De afkorting staat voor Focused ultrasound technologie. Die technologie kan zorgen voor openingen voor medicijnen in de bloed hersen barrière. Er vindt wereldwijd onderzoek plaats voor 30 hersenaandoeningen. Ook bij het Prinses Maxima centrum in Utrecht dat zich focust op kinderkamer start begin 2023 onderzoek met een nieuw apparaat voor deze technologie. Opent dit mogelijkheden voor Arrowhead en zijn zij daar ook mee bezig?
1 partner van Arrowhead die een ander overneemt..
Die is hier gauw genoeg weer. :-)
Hulskof schreef op 14 december 2022 18:36 :
Die is hier gauw genoeg weer. :-)
Heel opvallend dat nu 4finance hier ook niet meer schrijft.
de tuinman schreef op 15 december 2022 13:57 :
[...]
Heel opvallend dat nu 4finance hier ook niet meer schrijft.
Onzin, er is weinig tot geen nieuws bij Arrowhead. Richt je tot Arrowhead. Je vriendje zal snel weer terug komen. Ik hoop dat hij zich gaat gedragen.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee